Manager TitleAgeSince
Chief Executive Officer 58 2021-08-31
President 58 -
Director TitleAgeSince
Director/Board Member 58 2021-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
11/9/23 Others 101,010 0.0188%
11/9/23
a16z Capital Management LLC
TenderCompany 59,695,246 11.1045%
11/9/23 Exercice

Chief Executive Officer

16,136,833 3.0018%
Change 5-day change 1-year change 3-year change Capi.($)
-2.09%-.--% - - 1.14B
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.45%-1.22%+33.07%+180.54% 44B
Weighted average by Cap. -1.48%-1.85%+31.83%+155.14%
Logo EQRx, Inc.
EQRx, Inc. is a pharmaceutical company. The Company is engaged in developing medicines for some of the prevalent disease areas, including cancer and immune-inflammatory conditions. The Company brands include EQRx and Remaking Medicine. The Company's pipeline is comprised of approximately 10 programs, including both small molecules and biologics, with five clinical-stage programs, and several disclosed and undisclosed preclinical and drug engineering programs. Its clinical programs include Aumolertinib (EQ143), Lerociclib (EQ132), and Sugemalimab (EQ165). Aumolertinib (EQ143) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lerociclib (EQ132) is a novel and oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Sugemalimab (EQ165, also known as CS1001) is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody.
Employees
362
  1. Stock Market
  2. Stocks
  3. EQRX Stock